Rethinking the Treatment of Actinic Keratosis

Name: Rethinking the Treatment of Actinic Keratosis - On-demand Webinar
Uploaded: 2021-10-15T04:00:00+00:00
Description: This webinar featuring Anthony M. Rossi, MD, FAAD, will discuss the etiology of actinic keratosis and the risk for progression to squamous

Media formats available:

Details

Presenters

Overview
This webinar featuring Anthony M. Rossi, MD, FAAD, will discuss the etiology of actinic keratosis and the risk for progression to squamous cell carcinoma. Dr. Rossi will also describe field and light-based treatments for this condition and share his experience in formulating effective strategies for long-term management of patients with actinic keratosis, including appropriate monitoring, risk assessment, and behavioral modifications.
The presentation concludes with a previously recorded live Q&A session.
This activity is supported by an unrestricted medical education grant from Biofrontera.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Understand the etiology of actinic keratosis and describe the risk for progression to squamous cell carcinoma.
- Identify challenges associated with existing topical therapies and cryotherapeutic modalities and list potential benefits and limitations of these treatments.
- Describe light-based treatments for actinic keratosis, including photodynamic therapy.
- Describe the mechanism of action and list potential benefits and limitations of these modalities.
- Identify candidates for photodynamic therapy, define optimal treatment protocols, and outline short-term management strategies.
- Formulate effective strategies for long-term management of the AK patient, including appropriate monitoring, risk assessment, and behavioral modifications, including use of SPF and UV avoidance.
Accreditation
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Education
PAs may claim a maximum of 0.75 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines. This activity is designated for .25 pharmacology credits.
Faculty and Disclosures
Anthony M. Rossi, MD, FAAD
Dermatologic, Mohs, & Laser Surgery
Assistant Professor
Weill Cornell Medical College
Assistant Attending
New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
New York, NY

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Anthony M. Rossi, MD, FAAD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan. Consultant: Almirall, Biofrontera, Canfield Scientific, Dynamed, Evolus, Lam Therapeutics, Merz, Quantia MD, and Regeneron Pharmaceuticals. Grant/Research Support: Biofrontera, Leo Pharma, and Regeneron Pharmaceuticals. Speaker’s Bureau: Almirall, and Biofrontera.
The Evolve staff and planners have no financial relationships with commercial interests.
Neill T. Peters, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Biofrontera.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 10/15/2021
Expiration Date: 10/14/2022